Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Daniela Fera"'
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Elicitation of broadly neutralizing antibodies (bnAbs) is a goal of vaccine design as a strategy for targeting highly divergent strains of HIV-1. Current HIV-1 vaccine design efforts seek to elicit bnAbs by first eliciting their precursors through pr
Externí odkaz:
https://doaj.org/article/cfd84dd8cff54de4bcced95ae9de418f
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Externí odkaz:
https://doaj.org/article/5a4f6fe12eda48519468460e9b6eb40b
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Understanding affinity maturation of antibodies that can target many variants of HIV-1 is important for vaccine development. While the antigen-binding site of antibodies is known to mutate throughout the co-evolution of antibodies and viruses in infe
Externí odkaz:
https://doaj.org/article/b44af998088544369544cebed2469028
Autor:
Daniela Fera, Matthew S. Lee, Kevin Wiehe, R. Ryan Meyerhoff, Alessandro Piai, Mattia Bonsignori, Baptiste Aussedat, William E. Walkowicz, Therese Ton, Jeffrey O. Zhou, Samuel Danishefsky, Barton F. Haynes, Stephen C. Harrison
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
The V3 region of HIV Env elicits broadly neutralizing antibodies (bnAbs) in patients and represents a potential vaccine antigen. Here, Fera et al. show that the structure of a synthetic V3-glycopeptide closely resembles the conformation in intact HIV
Externí odkaz:
https://doaj.org/article/48c82e6eccb2413292faad0ffabddfee
Autor:
Wilton B. Williams, Jinsong Zhang, Chuancang Jiang, Nathan I. Nicely, Daniela Fera, Kan Luo, M. Anthony Moody, Hua-Xin Liao, S. Munir Alam, Thomas B. Kepler, Akshaya Ramesh, Kevin Wiehe, James A. Holland, Todd Bradley, Nathan Vandergrift, Kevin O. Saunders, Robert Parks, Andrew Foulger, Shi-Mao Xia, Mattia Bonsignori, David C. Montefiori, Mark Louder, Amanda Eaton, Sampa Santra, Richard Scearce, Laura Sutherland, Amanda Newman, Hilary Bouton-Verville, Cindy Bowman, Howard Bomze, Feng Gao, Dawn J. Marshall, John F. Whitesides, Xiaoyan Nie, Garnett Kelsoe, Steven G. Reed, Christopher B. Fox, Kim Clary, Marguerite Koutsoukos, David Franco, John R. Mascola, Stephen C. Harrison, Barton F. Haynes, Laurent Verkoczy
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-20 (2017)
An efficient HIV-1 vaccine will likely depend on eliciting broadly neutralizing antibodies (bnAb). Here the authors analyze the B cell repertoire in macaques and knock-in mice in response to sequential immunization with Env variants that induce a bnA
Externí odkaz:
https://doaj.org/article/69f91741f8e94cd5827c2664a8377d65
Publikováno v:
Viruses, Vol 13, Iss 9, p 1774 (2021)
Antibodies that can neutralize diverse HIV-1 strains develop in ~10–20% of HIV-1 infected individuals, and their elicitation is a goal of vaccine design. Such antibodies can also serve as therapeutics for those who have already been infected with t
Externí odkaz:
https://doaj.org/article/c802175702db4a77a09afc4ba9502c54
Autor:
Maxwell T. Finkelstein, Adam G. Mermelstein, Emma Parker Miller, Paul C. Seth, Erik-Stephane D. Stancofski, Daniela Fera
Publikováno v:
Viruses, Vol 13, Iss 1, p 134 (2021)
Coronavirus research has gained tremendous attention because of the COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus (nCoV or SARS-CoV-2). In this review, we highlight recent studies that provide atomic-resolution
Externí odkaz:
https://doaj.org/article/c5c27bfe5b7743df8ccd1b03f414170f
Autor:
Todd Bradley, Daniela Fera, Jinal Bhiman, Leila Eslamizar, Xiaozhi Lu, Kara Anasti, Ruijung Zhang, Laura L. Sutherland, Richard M. Scearce, Cindy M. Bowman, Christina Stolarchuk, Krissey E. Lloyd, Robert Parks, Amanda Eaton, Andrew Foulger, Xiaoyan Nie, Salim S. Abdool Karim, Susan Barnett, Garnett Kelsoe, Thomas B. Kepler, S. Munir Alam, David C. Montefiori, M. Anthony Moody, Hua-Xin Liao, Lynn Morris, Sampa Santra, Stephen C. Harrison, Barton F. Haynes
Publikováno v:
Cell Reports, Vol 14, Iss 1, Pp 43-54 (2016)
Antibodies that neutralize autologous transmitted/founder (TF) HIV occur in most HIV-infected individuals and can evolve to neutralization breadth. Autologous neutralizing antibodies (nAbs) against neutralization-resistant (Tier-2) viruses are rarely
Externí odkaz:
https://doaj.org/article/bc12b2e2dfd24166af9dc28af3fc9226
Autor:
David Easterhoff, M Anthony Moody, Daniela Fera, Hao Cheng, Margaret Ackerman, Kevin Wiehe, Kevin O Saunders, Justin Pollara, Nathan Vandergrift, Rob Parks, Jerome Kim, Nelson L Michael, Robert J O'Connell, Jean-Louis Excler, Merlin L Robb, Sandhya Vasan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, Sorachai Nitayaphan, Faruk Sinangil, James Tartaglia, Sanjay Phogat, Thomas B Kepler, S Munir Alam, Hua-Xin Liao, Guido Ferrari, Michael S Seaman, David C Montefiori, Georgia D Tomaras, Stephen C Harrison, Barton F Haynes
Publikováno v:
PLoS Pathogens, Vol 13, Iss 2, p e1006182 (2017)
The canary pox vector and gp120 vaccine (ALVAC-HIV and AIDSVAX B/E gp120) in the RV144 HIV-1 vaccine trial conferred an estimated 31% vaccine efficacy. Although the vaccine Env AE.A244 gp120 is antigenic for the unmutated common ancestor of V1V2 broa
Externí odkaz:
https://doaj.org/article/ac77c8a72fe944fc9406e5f67c47cb34
Publikováno v:
The FASEB Journal. 36